Legal & Compliance
Regenerative Medicine Disclosure
Effective Date: November 2, 2026
Investigational Therapies Notice
Cyberdrip Health offers regenerative therapies that use your own blood, such as platelet-rich plasma (PRP) and platelet-rich fibrin (PRF). Some uses of these therapies are considered emerging and may not be evaluated or approved by the FDA for the specific indications described on this website.
This disclosure explains the nature, regulatory status, and clinical considerations for the regenerative therapies offered by Cyberdrip Health.
Regulatory Status of Regenerative Therapies
Regenerative therapies, including PRP and PRF, may be:
- •Considered emerging or investigational treatments
- •Not evaluated by the FDA for specific medical uses
- •Available through clinical discretion based on current medical literature
- •Subject to state-by-state regulatory requirements
Patients will be fully informed of the regulatory status of any proposed regenerative therapy during consultation.
Clinical Evaluation and Provider Oversight
Treatment decisions for regenerative therapies are made exclusively by licensed medical providers based on:
- •Comprehensive clinical evaluation and patient history
- •Diagnostic findings and biomarker analysis
- •Patient goals and clinical appropriateness
- •Available evidence-based medical literature
Eligibility for regenerative medicine services is determined exclusively during the clinical evaluation process. Not all patients are candidates for these therapies.
Patient Outcomes and Results
Results vary from patient to patient. Cyberdrip Health makes no guaranteed claims regarding specific outcomes from regenerative therapies. Individual response depends on:
- •Individual physiology and genetics
- •Age and overall health status
- •Adherence to care recommendations
- •Lifestyle and environmental factors
Testimonials or descriptions of outcomes reflect individual experiences and are not intended to imply typical or guaranteed results.
Disease Claims Limitation
Regenerative therapies offered by Cyberdrip Health are not intended to diagnose, treat, cure, or prevent disease unless specifically approved for that use by the FDA or applicable regulatory authority. Services are offered within the scope of clinical appropriateness, after an evaluation by a licensed provider.
Risks and Informed Consent
Like all medical interventions, regenerative therapies carry potential risks. Patients will receive comprehensive information including:
- •Potential benefits based on current evidence
- •Known and potential risks and side effects
- •Alternative treatment options
- •Regulatory and investigational status of the therapy
Informed consent is required before any regenerative therapy is administered. Patients are encouraged to ask questions and discuss concerns with their provider.
By pursuing regenerative medicine services with Cyberdrip Health, you acknowledge your understanding of this Disclosure and the emerging nature of certain uses of these therapies.